Takeda (Tokyo, JP / Cambridge, MA) sponsors 192 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 63 active protocols (43 recruiting now), 95 completed protocols, and 63 all-time original FDA Drugs@FDA NDA and BLA approvals.